Phase I/IIa Study of Combination Chemotherapy with CKD-602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer

The aim of this study was to determine the maximum tolerated dose (MTD) and therapeutic efficacy of a newly developed CKD‐602 topoisomerase I inhibitor and cisplatin in patients with recurrent epithelial ovarian cancer. CKD‐602 (0.30 mg/m2 daily for 5 days) and cisplatin (60 mg/m2 on day 5) were adm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the New York Academy of Sciences 2009-08, Vol.1171 (1), p.627-634
Hauptverfasser:	Kim, Hee Seung, Kang, Sok-Bom, Seo, Sang-Soo, Han, Seung-Su, Kim, Jae Weon, Park, Noh-Hyun, Kang, Soon-Beom, Lee, Hyo-Pyo, Song, Yong Sang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anemia - chemically induced Anorexia - chemically induced Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects CKD-602 Epithelial Cells - pathology Female Humans Leukopenia - chemically induced Middle Aged Nausea - chemically induced Neoplasm Recurrence, Local Neoplasm Staging Neutropenia - chemically induced ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology recurrent Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!